Treatment of neovascular age-related macular degeneration in patients with diabetes by OCT), should take into consideration the association of diabetic retinopathy and the possible presence of chronic dif- fuse cystoid edema. Another factor that must be considered in patients with diabetes is their potential increased susceptibil- ity to the side effects associated with the drugs administered repeatedly for neovascular AMD treatment. References Alberti KGMM, Zimmet PZ, on behalf of the World Health Organization (WHO). 1998. Deﬁnition diagnosis and classiﬁcation of diabetes mel- litus and its complications. Diab Med, 15:539–53. Ambati J, Ambati BK, Yoo SH, et al. 2003. Age-related macular degenera- tion: etiology, pathogenesis, and therapeutic strategies. Surv Ophthal- mol, 48:257–93. Bagust A, Hopkinson PK, Maier W, et al. 2001. An economical model of the long-term healthcare burden of type II diabetes. Diabetologia, 44:2140–55. Baxter H, Bottomley J, Harvey J, et al. 2000. CODE 2 UK: the current costs of type 2 diabetes in the UK. Diab Med, 17(S1):abstract. Brown DM, Kaiser PK, Michels M, et al. 2006. Ranibizumab versus verteporﬁn for neovascular age-related macular degeneration. N Engl J Med, 355:1432–44. Cunha-Vaz JG, Abreu, JRF, Campos AJ, et al. 2006.Early breakdown of the blood-retinal barrier in diabetes. Br J Ophthalmol, 59:649–56. Cunha-Vaz JG, Bernardes R. 2005. Non-proliferative retinopathy in diabetes type 2. Initial stages and characterization of phenotypes. Progr Retinal Eye Res, 24:355–77. Cunha-Vaz JG. 1975. Clinical characterization of diabetic macular edema. Int Ophthalmol, 1(4):99–100. Dabelea D, Hanson RL, Bennett PH, et al. 1998. Increasing evidence of type II diabetes in American Indian children. Diabetologia, 41:904–10. [DCCT] The Diabetes Control and Complications Trial Research Group. 1996. Lifetime beneﬁts and costs of intensive therapy as practiced in the DCCT. JAMA, 276:1409–15. [DECODE] Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe Study Group. 2003 Age- and sex-speciﬁc prevalence of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care, 26:61–9. Gavard JA, Lustman PJ, Clouse RE. 1993. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care, 16:1167–78. Gragoudas ES, Adamis AP, Cunningham Jr ET, et al. 2004. VEGF inhibi- tion study in ocular neovascularization clinical trial group: Pegaptanib for neovascular age-related macular degeneration. N Engl J Med, 351:2805–16. [GSK] GlaxoSmithKline. 2000. The true costs of type 2 diabetes in the UK – findings from the T2ARDIS and CODE-2. Uxbridge UK: GlaxoSmithKline. James M, Turner DA, Broadbent DM, et al. 2000. Cost effectiveness of screening for sight threatening diabetic eye disease. BMJ, 320:1627–31. Kannel WB, McGee DL. 1979. Diabetes and cardiovascular disease. The Framingham Study. JAMA, 241:2035–38. King H, Aubert RE, Herman WH. 1998. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care, 21:1414–31. Klein R, Klein BE, Moss SE. 1992. Diabetes, hyperglycemia, and age- related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99:1527–34. Puliaﬁto CA, Hee MR, Lin CP, et al. 1995: Imaging of macular disease with optical coherence tomography. Ophthalmology, 102:217–229. Rewers M, LaPorte RE, King H, et al. 1988. Trends in the prevalence and incidence of diabetes; insulin dependent diabetes in childhood. World Health Stat Q, 41:179–89. Rosenfeld PJ, Brown DM, Heier JS, et al. 2006. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med, 335:1419–31. Sander B, Larsen M, Moldow B, et al. 2001. Diabetic macular edema: pas- sive and active transport of ﬂuorescein through the blood-retina barrier. Invest Opthalmol Vis Sci, 42:433–8. Shotliff K, Duncan G. 2005. Diabetes and the eye. In Shaw KM, Cum- mings MH (eds). Diabetic complications. Chichester UK: John Wiley and Sons. p. 1–19. Slakter JS, Yannuzzi LA, Schneider U, et al. 2000. Retinal choroidal anas- tomoses and occult choroidal neovascularization in age-related macular degeneration. Ophthalmology, 107:742–53. Steck AK, Rewers MJ. 2004. Epidemiology and geography of type 1 diabetes. In DeFronzo RA, Ferrannini E, Keen H, et al. (eds). Inter- national textbook of diabetes. Chichester UK: John Wiley and Sons. p. 15–31. [UKPDS] United Kingdom Prospective Diabetes Study Group. 2000. Cost effectiveness analysis of an intensive blood glucose control policy in patients with type 2 diabetes; economic study analysis alongside ran- domised controlled trial (UKPDS41) BMJ, 320:1373–8. Urakami T, Inami I, Morimoto S, et al. 2002. Clinical characteristics of non-immune mediated, idiopathic type 1B diabetes mellitus in Japanese children and adolescents. J Paediatr Endocrinol Metab, 15:283–8. Voutilainen-Kaunisto RM, Teräsvirta ME, Uusitupa MIJ, et al. 2000. Age- related macular degeneration in newly diagnosed type 2 diabetic patients and control subjects. Diabetes Care, 23:1672–8. [WHO] World Health Organization. 1999. Deﬁnition, diagnosis and clas- siﬁcation of diabetes mellitus and its complications. Report of a WHO Consultation Part 1: Diagnosis and Classiﬁcation of Diabetes Mellitus. Geneva:WHO. Yannuzzi LA, Sorenson J, Spaide RF, et al. 1990. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina, 10:1–8 Zeimer R, Mori MT, Khoobebi B. 1989. Feasibility test of a new method to measure retinal thickness non-invasively. Invest Ophthalmol Vis Sci, 30:2099–105. Zylbermann R, Landau D, Rozenman Y, et al. 1997. Exudative age-related macular degeneration in patients with diabetic retinopathy and its rela- tion to retinal laser photocoagulation. Eye, 11:872–5. Clinical Ophthalmology 2008:2(2) 375